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Abstract 
Intermediate lipid structures uch as inverted micelles and interlamellar attachments are thought o play a crucial role in different 
biological processes like exocytosis, intracellular trafficking and viral infection. In the present study, we provide evidence that lipid 
mixing of large unilamellar lipid vesicles (LUV) mediated by the NH.-terminal sequence of the SIV gp32 and of HIV gp41 is inhibited 
by external addition of lysophosphatidylcholine (lysoPC) to LUV containing phosphatidyletbanolamine in their lipid bilayer. Leakage 
experiments confirm that lysoPC enhances the stability of the lipids organization. The temperature dependence of the two processes as 
well as the complementary shape of PE and lysoPC suggest hat the PE-lysoPC interaction is involved in the fusion inhibition and 
stabilization of the bilayer. 
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1. Introduction 
Membrane fusion is an essential event in cell biology 
and it has been extensively studied in the recent years, and 
more particularly the enveloped virus-host cell fusion event. 
With regard to the human immunodeficiency virus, unlike 
the binding of gpl20 to CD4 [1] the postbinding molecular 
events leading to HIV-mediated membrane fusion are much 
less well understood even though major conformational 
changes of the whole gpl20/gp41 complex are involved, 
resulting in the exposure of the gp41 N-terminal fusogenic 
domain [2]. This mechanism is crucial not only for the 
penetration of free virus into cells but also for cell fusion 
processes that can lead to syncytium formation [3]. Most 
viral fusogenic proteins contain a short amino-terminal 
hydrophobic segment which interacts with the lipid mem- 
brane during the fusion event [4,5]. Mutagenesis tudies 
have confirmed that modifications disrupting the distribu- 
tion of the hydrophobic amino acids in the N-terminus of 
Influenza hemagglutinin [6], gp41 of HIV [2,1] and gp32 
of SIV [7,8] inhibit syncytium formation without affecting 
glycoprotein synthesis and processing or receptor binding, 
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suggesting that hydrophobicity plays a key role in the 
fusion process. 
Although fusion requirements for simple membrane 
model systems are often far from those known to be 
required for biological membranes, uch studies have un- 
doubtedly contributed to a molecular description of differ- 
ent steps of the fusion process. One of the main contribu- 
tions has been to assess the role of lipid transient species 
like inverted micelles and hexagonal phases in the fusion 
mechanism. If it is accepted that fusion peptides interact 
with the lipids of the target membrane [4,9-11] to produce 
hexagonal lipid structures of negative curvature [12,13], 
the molecular mechanism of such a process remains un- 
known. Although phopholipids in biological membranes 
are mainly arranged as a bilayer, a fraction of the total 
lipids form inverted structures. This phase preference has 
been related to the average shape of the molecules. Bilayer 
preferring lipids are thought o adopt an overall cylindrical 
shape. In contrast, lipids which form an inverted hexagonal 
(H H) phase are thought to be conical with the polar 
headgroup at the smaller end of the cone as phosphatidyl- 
ethanolamine (PE). Lysophosphatidylcholine (lysoPC), 
with its relatively large hydrophilic moiety, prefers micel- 
lar organizations in excess water. Addition of lysoPC to 
the contacting monolayers of artificial planar lipid mem- 
branes was shown to inhibit the monolayer fusion [14]. 
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Moreover, lysoPC has been shown to inhibit diverse bio- 
logical fusion processes as exocytosis and virus-mediated 
syncytia formation [15]. This inhibition was not related to 
solubilization of requisite fusion components, irreversible 
denaturation, or membrane lysis. The apparently universal 
character of the phenomenon suggested that lysolipids 
inhibit an intermediate step common for all fusion reac- 
tions [15]. 
We have previously reported that a synthetic peptide 
corresponding to the 12 amino acids of the N-terminus of 
SIV gp32 and to the 16 amino acids of the N-terminus of 
HIV gp41 induced the fusion of large unilamellar vesicles, 
provided the liposomes contained PE in their lipid bilayer 
[10,16]. In the present paper, to test whether the vesicles 
fusion induced by the SIV/HIV fusion peptide shares a 
common mechanistic step with the biological virus-cell 
fusion, we studied the role of exogenous lysoPC in the 
lipid fusion process induced by those peptides. 
nitrile (between 65 and 75%) using a linear gradient over 
30 min from 10 to 90% acetonitrile with 0.1% trifluoro- 
acetic acid. The sequence was verified by protein sequenc- 
ing on an Applied Biosystem sequencer. The peptide was 
dissolved in TFA, and after evaporation of the solvent, 
DMSO was added to a final peptide concentration of 
8 • 10 -4  M. The stock solutions were stored at 0°C. 
Vesicles preparation 
Multilamellar vesicles (MLV) were obtained by vortex- 
ing a lipid film in a Tris buffer (10 mM Tris, 150 mM 
NaCI, 0.1 mM EDTA, 0.02% NaN 3, pH 7.4). 
Large unilamellar vesicles (LUV) were prepared ac- 
cording to the extrusion procedure of Hope et al. [18] using 
an Extruder (Lipex Biomembranes, Vancouver, Canada). 
Briefly, frozen and thawed MLV were extruded l0 times 
through two stacked polycarbonate membranes with a pore 
size of 0.1 /xm (Nucleopore, Pleasanton, CA, USA). 
2. Materials and methods 
2.1. Materials 
Egg phosphatidylethanolamine (PE), egg phosphatidyl- 
choline (PC), cholesterol (Chol), sphingomyelin (SM), 
lysophosphatidylcholine (lysoPC), and Triton X-100 were 
purchased from Sigma (St. Louis, MO, USA). N-(Nitro- 
benzo-2-oxa- 1,3-diazol)phosphatidylethanolamine (NBD- 
PE) and N-(lissamine rhodamine B sulfonyl)phosphatidyl- 
ethanolamine (Rh-PE) were from Avanti Polar Lipids 
(Birmingham, AL, USA). 
Calcein (Sigma) was purified by chromatography on 
Sephadex LH20 (Pharmacia). Calcein was loaded on the 
column as a sodium salt solution and eluted with water at 
neutral pH. The concentration of calcein was determined 
spectrophotometrically by using 7.0. 10 4 as  the molar 
extinction coefficient at 492 nm [17]. 
2.2. Methods 
Peptide synthesis 
Peptides (Fig. 1) were synthesized by solid-phase syn- 
thesis using a commercially available peptide synthesizer 
(model Biolynx, Pharmacia Biochrome, Cambridge, UK) 
and the preweighted Fmoc amino acid (Pharmacia 
Biochrome, Cambridge, UK). Acylation rate was moni- 
tored by the Bioplus software be measuring the release of 
an anionic dye (Acid violet 17.3 mg/100 ml dimethyl- 
formamide and 0.14 ml diisopropylethylamine) at 600 nm. 
The peptides were cleaved from the resin using trifluoro- 
acetic acid containing 2% anisol and 2% ethanedithiol for 
2 h followed by ether precipitation. Each peptide was 
purified to more than 95% purity by HPLC on a C18 
Alltima reverse phase column (7.5 X 300 ram) (Alltech, 
Belgium). The peptides typically eluded at 65% aceto- 
Assay of vesicle leakage 
Dry lipid films were rehydrated toa concentration f 20 
mg/ml in 10 mM Hepes pH 7.2 buffer containing 62 mM 
calcein purified as described above. Unencapsulated dye 
was removed by passing the liposome preparation over a 
Sephadex G50 gel filtration column, equilibrated with 10 
mM Hepes, 150 mM NaC1, 1 mM EDTA buffer, pH 7.2. 
Liposome concentration was estimated by measuring lipid 
phosphorus content [19]. 
Release of the fluorescent dye from preloaded LUV at a 
final lipid concentration of 3. 10 -4  M, was monitored 
using SLM 8000 fluorometer (SLM Instruments, Urbana, 
IL). Experiments were conducted in a 1 ml stirred cuvette, 
with fight angle illumination. Excitation and emission 
wavelengths were set at 490 nm and 520 nm, respectively, 
employing a slit width of 4 nm. The addition of Triton 
X-100 to a final concentration of 0.1% (v/v)  was used to 
determine maximal release. The percentage of total fluo- 
rescence was defined as 
/,-/0 
%F t - -  × 100 
1100 - 10 
where I o is the initial fluorescence, 1100 is the total 
fluorescence observed after addition of Triton X-100, and 
I, is the fluorescence observed after addition of SIV/HIV 
fusion peptide at t = 600 s, corrected for dilution. 
Assay of vesicle fusion 
Lipid mixing was determined by measuring the fluores- 
cence intensity change resulting from the fluorescence 
energy transfer between the probes NBD-PE and Rh-PE, 
as described by Struck et al. [20]. Fluorescence was moni- 
tored using a SLM 8000 spectrofluorimeter in the same 
conditions described for the leakage assay, excepted for 
the excitation and emission wavelengths which are 470 nm 
I. Martin, J.-M. Ruysschaert / Biochimica et Biophysica Acta 1240 (1995) 95-100 
HIV 16aa fusion peptide: 
NH2-AIa-VaI-GIy-IIe-GIy- Ala-Leu-Phe-Leu-Gly-Phe-Leu-Gly-Ala-Ala-Gly_COOH 
SIV 12 aa fusion peptid¢: 
NH2-Gly-Val-Phe-Val-Leu-Gly-Phe-Leu-Gly-Phe-Leu-Ala-C OOH 
Fig. 1. SIV and HIV fusion peptides equences. 
97 
and 530 nm, respectively. Both probes were added to the 
lipid film and LUV were prepared as described above. 
Liposomes containing both probes at 0.6% (molar ratio) 
each, were mixed in a 1:9 mol ratio with probe free 
liposomes at a final lipid concentration f 3 • 10  -4  M. The 
initial fluorescence of the 1:9 (labeled/unlabeled) suspen- 
sion was taken as 0% fluorescence and the 100% fluores- 
cence was determined using an equivalent concentration f
vesicles prepared with 0.06% of each fluorescent phospho- 
lipid. 
3. Results 
3.1. LysoPC inhibits the lipid mixing 
The ability of SIV and HIV fusion peptides (Fig. 1) to 
induce intervesicular lipid mixing of LUV has been 
demonstrated by measuring the dilution of fluorescent 
lipids (NBD-PE, Rh-PE) occurring during mixing of fluo- 
rescently labeled and unlabeled population of vesicles [20]. 
SIV peptide as well as HIV fusion peptide were shown to 
catalyze lipid mixing of vesicles composed of 
PC/PE /SM/Cho l  (1:1:1:1.5 molar ratio) and PC/PE 
(1:1 or 2:1 molar ratio) with an enhancement of the fusion 
rate in the bilayer-hexagonal phase transition temperature 
range of pure egg PE [11,16]. Moreover, the fusion process 
was shown to increase with the concentration f PE in the 
lipid bilayer suggesting its direct involvement in the fusion 
mechanism [11]. Here, we provide evidence that addition 
of exogenous lysoPC to the medium resulted in a concen- 
tration dependent inhibition of the liposome fusion (Fig. 
2). The PC/PE /SM/Cho l  composition is the most repre- 
sentative of the plasma membrane and has been shown to 
be highly fusogenic [10,16]. The inhibiting amount of 
lysoPC increases with the amount of PE present in the 
vesicles lipid bilayer, suggesting a direct relationship be- 
tween these two lipids and the inhibition of the fusion step 
(Table 1). This inhibition was observed whether LUV were 
pre-incubated with lysoPC before addition of fusion pep- 
tide or whether peptide and lysoPC were added simultane- 
ously to the vesicles suspension. At lysoPC concentration 
of 45 /xM, inhibition is complete whatever the lipid vesi- 
cles composition. Addition of more peptide (15 /zM to 40 
/~M) induced a high rate of vesicles aggregation but no 
lipid mixing, suggesting that the vesicles where unable to 
fuse even in the presence of an excess of fusogenic agent 
(data not shown). It should be mentioned that lysis of the 
vesicles was only observed above 350/zM lysoPC (Fig. 2) 
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Fig. 2. LysoPC inhibition effect of lipid mixing of LUV PC/PE /SM/Cho l  ( 1 : 1 : 1 : 1.5 molar ratio) vesicles induced by SIV and HIV fusion peptides added 
from DMSO. LUV (300/zM) and lysoPC (at different concentration) were preincubated at 37°C pH 7.2 in Hepes buffer, for 15 min prior the addition of 
peptide (13 /xM). The open symbols refer to the percentage of lipid mixing while the filled circles refer to the lysis of vesicles. 
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Fig. 3. LysoPC inhibition effect of calccin leakage of LUV PC/PE/SM/Cho l  (l:l:hl.5 molar ratio) vesicles induced by SIV and H|V fusion peptide 
added from DMSO.  LUV (300 p,M) and lysoPC (at different conccntration) wcre preincubated at 37°C pH 7.2 in Hepcs buffer, for 15 min prior the 
addition of pcptide ( 13 p,M). 
3.2. LysoPC stabilizes the lipid organization 
We have shown that the SIV/HIV fusion peptides 
favor the leakage of calcein encapsulated in LUV aqueous 
contents of PC /PE /SM/Cho l  (1 : ! : 1:1.5 molar ratio) and 
PC/PE (1:1 and 2:1 molar ratio) in a time-dependent and 
dose-dependent manner [11,16]. A rapid burst of leakage 
was observed approx. 30 s after addition of peptide, fol- 
lowed by a slower phase. Here, the leakage of liposome 
aqueous content was examined in the presence of exoge- 
nous lysoPC and as a function of temperature. Liposomes 
of PC/PE (1:1 and 2:1 molar ratio) or PC/PE /SM/Cho l  
(1 : 1:1:1.5 molar ratio) were incubated with various amounts 
of lysoPC at 37°C. After 30 min of incubation, the pep- 
tides were added to liposomes, and the calcein fluores- 
cence was measured. Fig. 3 demonstrates that lysoPC 
stabilizes the lipid organization and reduce drastically the 
lipid permeability. As for the lipid mixing, the inhibitory 
amount of lysoPC increases with the amount of PE present 
in the lipid bilayer (data not shown). 
3.3. LysoPC modified the bilayer-non lamellar lipid struc- 
ture transition 
Lipid mixing and leakage induced by SIV in the ab- 
sence and in the presence of lysoPC depend on tempera- 
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Fig. 4. Temperature d pendence oflipid mixing (A) and calcein leakage (B) of LUV PC/PE/SM/Chol (1 : 1:1 : 1.5 molar atio) vesicles induced by SIV in 
the absence and the presence of lysoPC. LUV (300 ~M) and lysoPC (70 /~M) were preincubated at37°C pH 7.2 in Hepes buffer, for 15 rain prior the 
addition of SIV (13 /~M). 
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Table I 
LysoPC inhibition of lipid mixing induced by SIV and HIV fusion 
peptides as a function of PE concentration 
LysoPC % of inhibition 
concentration 13/xM PE 
(/xM) 
6 /xM PE 3/xM PE 
SIV HIV SIV HIV SIV HIV 
0 0 0 0 0 0 0 
5 30 28 45 50 50 55 
10 53 50 60 60 65 67 
20 63 62 70 75 80 85 
30 80 81 90 95 100 100 
40 94 90 100 100 100 100 
45 100 100 100 100 100 100 
LUV (300 /xM) and lysoPC (at different concentrations) were preincu- 
bated at 37°C pH 7.2 in Hepes buffer, for 15 min prior the addition of 
SIV/HIV fusion peptides (13 /~M). 
ture as shown in Fig. 4. Without lysoPC, the mixing of the 
lipid phases as well as the leakage of the encapsulated 
aqueous content increase steeply between 30°C and 40°C. 
It is in this temperature range that the transition of PE 
from a bilayer to a non lamellar lipid structures occurs (the 
transition temperature of egg-PE MLV is between 38°C 
and 45°C) [21]. In the presence of exogenous lysoPC, this 
transition temperature is shifted to the right suggesting a
stabilizing effect of lysoPC. This shift was observed in the 
vesicle leakage and lipid mixing experiments not only for 
the SIV fusion peptide but also for the HIV fusion peptide 
(data not shown). This could be interpreted in term of the 
molecular shape concept. In an equimolar mixture of the 
inverted cone-shaped lysoPC and the cone shaped unsatu- 
rated PE, lysoPC stabilizes the lipid bilayer organization 
and increases of about 10°C the transition temperature 
from a bilayer to a non lamellar lipid structures [22]. 
4. Discussion 
The aim of this study was to investigate the possible 
relationship between peptide-induced fusion of large unil- 
amellar vesicles and the formation of non lipid bilayer 
structures, using the SIV and HIV fusion peptides as 
model peptides. We have more particularly focused on the 
role of the lipid bilayer in the fusion process. One impor- 
tant question is whether lipids which are competent to 
form inverted phases can enhance the protein-mediated 
fusion mechanism [23]. 
The data demonstrate that the SIV and HIV fusion 
peptides induce the fusion of large unilamellar vesicles 
containing PE in their lipid bilayer [11,16], which can form 
inverted phases on its own, supporting the hypothesis of 
the formation of the HI! phase during membrane fusion. 
PE has also been shown to enhance the rate of Influenza 
virus-induced membrane fusion [25]. The pH-induced fu- 
sion of peptide Sindbis virus with model membrane is also 
dependent on the acyl chain composition of the target 
membrane and is greatly enhanced by the presence of type 
II non bilayer lipid such as PE or cholesterol in these 
membranes [24]. The fact that HI1 phase-competent lipid 
bilayers enhance the fusion rate of different systems 
strongly suggests that H H phases are involved in this 
process. 
The SIV/HIV-induced vesicle fusion is accompanied 
by a rapid leakage of encapsulated solute like calcein. This 
leakage has also been observed uring LUV fusion in- 
duced by gramicidin A [25]. It has been suggested in the 
case of gramicidin A that the leakage is mechanistically 
related to HI~ phase formation which is expected to result 
in a loss of vesicle integrity and thus a release of the 
enclosed contents [26]. 
In the present paper, we have shown that the fusogenic 
activity (lipid mixing) of the SIV/HIV fusion peptides is 
inhibited by exogenous lysoPC in a dose dependent and 
temperature d pendent way. Since the sequence of the HIV 
fusion peptide is distinct from that of SIV, the inhibiting 
effect of lysoPC depends on the vesicles lipid membrane 
composition suggesting that the physicochemical mecha- 
nism of inhibition is directly related to membrane lipids 
properties. 
The mechanism responsible for the lysoPC inhibition is 
still unclear, however our data are consistent with a 
lysoPC-lipid interaction. Recently, different amphiphilic 
molecules have been tested to determine the features of 
lysolipids responsible for fusion inhibition [15]. Inhibition 
did not correlate with any specific chemical moiety of 
lysolipids hut rather with their specific inverted conical 
shape [15]. This along with the ability of lysolipids to 
inhibit the fusion occurring between cell membrane or- 
ganelles and between organelles and plasma membrane 
induced by several distinct fusogenic agents like Ca 2+, 
GTP or viral fusion peptide [15] suggests that lysolipids 
act by altering a common motif of membrane fusion, and 
more particularly the ability of membranes to form highly 
curved 'stalk' intermediates. Regarding our results, this 
common motif seems also to be present in our model 
system suggesting a similar mechanism between SIV/HIV 
peptide-induced vesicle fusion and virus-induced syncytia 
formation. 
If lipid polymorphism is important in biological pro- 
cesses uch as fusion and if in these processes, modulation 
of lipid structure is triggered by lipid-protein interactions, 
the question arises whether proteins will be able to induce 
changes in lipid phase behavior upon entering the mem- 
brane. It has been proposed that the fusion process in- 
volves the penetration of the fusion peptide into the target 
membrane favoring inverted phase formation. The SIV 
fusion peptide was also shown to lower the hexagonal 
transition temperature of palmitoleoylphosphatidyl- 
ethanolamine [27] suggesting that insertion of the fusion 
peptide into the target bilayer disrupts bilayer packing. 
Moreover, 3~P-NMR studies demonstrate he presence of 
H II phase structure for MeDOPE vesicles at 37°C in 
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presence of SIV fusion peptide [27]. The oblique orienta- 
tion of the fusion peptide into the lipid bilayer was shown 
to be required for the fusogenic activity. Peptides inserted 
parallel to a normal with respect o the lipid-water inter- 
face was not fusogenic [28] and did not affect significantly 
the bilayer-non lamellar phase transition temperature [29]. 
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